Hansa Biopharma announces positive Idefirix PAES results presented in the High-Impact Clinical Trials session at ASN Kidney Week
- The 1-year graft failure-free survival at 12 months post-transplant was 90%, which is clinically meaningful
- Graft and patient survival were 92% and 98%, respectively
- Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience
Lund, Sweden, October 23, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that data from the European Post-Authorization Efficacy and Safety (PAES) study of Idefirix® (imlifidase) were presented during the High-Impact Clinical Trials oral session at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado. The abstract “FR-OR103 Post-Authorization Efficacy and Safety (PAES): An Open-Label Post Authorization Trial of 50 Imlifidase Crossmatch-Positive Deceased-Donor Kidney Transplants in Europe” was selected as a Late-Breaking Abstract at the congress.
